Summary: This study aimed to establish a practical and simplified method of predicting intestinal availability in humans (F g,human ) at the drug discovery stage using in vitro metabolic clearance values and permeability clearance values. A prediction model for F g,human of 19 CYP3A substrates and 5 UGT substrates was constructed based on the concept that the permeability clearance values mean the permeability across the basal membrane with a pH of 7.4 on both sides. Permeability clearance values were obtained by parallel artificial membrane permeability assay (PAMPA) at pH 7.4. PAMPA is widely used in the pharmaceutical industry as the earliest primary screening stage and enables estimation of the kinetics of transport by passive diffusion. For CYP3A substrates, the metabolic clearance was obtained from in vitro intrinsic clearance values in human intestinal or hepatic microsomes (CL int,HIM or CL int,HLM , respectively). Using metabolic clearances corrected by the ratio of CL int,HIM to CL int,HLM , HLM showed equivalent predictability to that of HIM for CYP3A substrates. For UGT substrates, the clearance was obtained from alamethicin-activated HIM using one incubation with both NADPH and UDPGA cofactors. The method proposed in this study could predict F g,human for the compounds investigated and represents a simplified method based on a new concept applicable to lower permeability compounds.
Introduction
The oral route is the most convenient for administration of drugs, but it is often associated with low bioavailability because of first-pass metabolism in the liver and the intestine. To select high bioavailability compounds, attempts have been made to predict the extent of first-pass effects in humans by in vitro methods using subcellular fractions and cell lines. Although in vitro®in vivo predictions of hepatic metabolism have become widely accepted, the same approaches to intestinal metabolism have proved to be a greater challenge, and the results are less definitive.
1®4¥ For example, Yang et al. earlier reported that the Q gut model for in vitro®in vivo prediction of intestinal metabolism of cytochrome P450 ¤CYP¥ 3A substrates, which takes into account the interplay between permeability and metabolism, improved prediction as compared with the well-stirred model. 4¥ However, the Q gut model largely underestimated or overestimated the intestinal availability in humans ¤F g,human ¥ for some compounds. 5¥ We showed the appropriateness of the F g,human prediction model for CYP3A substrates using cynomolgus monkeys.
6¥
This method should be useful for accurate prediction of human bioavailability at the late stage of selection of candidate drugs because it gives a very good prediction of F g,human . Therefore, a simplified in vitro®in vivo prediction method for F g,human using in vitro metabolic clearance and permeability values at the early stage of selection of candidate drugs was developed. The merit of an in vitro® in vivo method is that it has potential for prediction through easy use of high-throughput screening data and is applicable to various metabolic enzymes. In the present study, the predictive ability of the method was investigated using uridine diphosphate glucuronosyltransferase ¤UGT¥ substrates in addition to CYP3A substrates.
Drugs that dissolve in the intestinal lumen are taken up in intestinal epithelial cells and then are either metabolized by intracellular drug-metabolizing enzymes or permeate across the basal membrane. 6¥ Substrates of efflux transporter, for example, P-glycoprotein ¤P-gp¥, are eliminated from the cells into the lumen via efflux transporters, but because they follow a similar route to that mentioned above, such substrates taken up in the intestinal epithelial cells are similarly either metabolized or permeate out of the cell. Therefore, regardless of whether a drug is an efflux transporter substrate or not, the method assumes that F g is prescribed by the intestinal metabolic clearance ¤CL met ¥ and the membrane permeability from within the cells ¤pH 7.4¥ to the blood ¤pH 7.4¥ ¤CL perm ¥. For these reasons, permeability values were obtained by parallel artificial membrane permeability assay ¤PAMPA¥ at pH 7.4, considering that the values represent the permeability across the basal membrane with a pH of 7.4 on both sides.
PAMPA, a passive permeability screening system, is used in the pharmaceutical industry as a low-cost alternative to cellular models for the earliest primary screening of the permeability of drugs across the intestinal wall. 7¥ PAMPA enables estimation of the kinetics of transport by passive diffusion without the need to incorporate active transport or paracellular permeability. Although cell lines are more physiologically relevant than PAMPA generally ¤Caco-2 cells are often used in other reports 5¥ ¥, PAMPA was used in the present study because CL perm means the permeability across the basal membrane without efflux transporters in this model. To confirm this concept, the results from PAMPA were compared with those from Caco-2 cells.
The CYP3A subfamily is the most important among all human drug-metabolizing enzymes because it is involved in the biotransformation of about 50% of the therapeutic drugs on the market. 8¥ CYP3A is reported to be the most abundant CYP subfamily in both human intestine and liver, and the percentage contributions to total immunoquantified CYP content are 40% and 82%, respectively. 9¥ It is now well known that many drugs metabolized by CYP3A undergo first-pass metabolism in the intestine.
There is an increasing awareness of the importance of glucuronidation, especially in drug development. 10¥ UGT and CYP3A are important metabolic enzymes that contribute to first-pass drug metabolism. In humans, the tissuedependent distribution of various UGT isoforms has been elucidated: the expressions of UGT1A1, 1A3, 1A4, 1A6, 1A9, 2B7, and 2B15 have been detected in the liver, whereas UGT1A7, 1A8, and 1A10 are absent. In human intestine, UGT1A1, 1A4, 1A8, and 1A10 have been detected. 11¥ Raloxifene, which exhibits a low oral bioavailability of only 2%, is metabolized by UGT1A8 and UGT1A10.
12¥ Therefore, it is suggested that intestinal glucuronidation catalyzed by UGT1A8 and UGT1A10 may play important roles in first-pass metabolism, causing low oral bioavailability. There is no report that predicts F g,human of UGT substrates, although UGT is important in intestinal first-pass metabolism.
The purpose of the present study was to develop a simplified in vitro®in vivo prediction method of intestinal first-pass metabolism for CYP3A substrates in humans.
Furthermore, prediction of F g,human of UGT substrates was attempted using this method. F g,human was calculated for 19 CYP3A substrates and 5 UGT substrates using in vitro metabolic clearance values and permeability values. For CYP3A substrates, the metabolic clearance was obtained from metabolic stability assays in human intestinal and hepatic microsomes ¤HIM and HLM, respectively¥. For UGT substrates, the clearance was obtained from those in alamethicin-activated HIM using one incubation with both NADPH and UDPGA cofactors. Permeability values were obtained by PAMPA at pH 7.4.
Materials and Methods
Chemicals: Carbamazepine, cisapride monohydrate, diclofenac sodium salt, ¤+¥-cis-diltiazem hydrochloride, gemfibrozil, nicardipine hydrochloride, nimodipine, raloxifene hydrochloride, telmisartan, terfenadine, ¤+¥-verapamil hydrochloride, flecainide acetate, and UDPGA ¤UDP-glucuronic acid¥ were purchased from Sigma Aldrich ¤St. Louis, MO, U.S.A.¥, and diazepam, midazolam, nifedipine, quinidine, and triazolam were purchased from Wako Pure Chemical Industries ¤Osaka, Japan¥. Buspirone hydrochloride, felodipine, and troglitazone were purchased from LKT Laboratories ¤St. Paul, MN, U.S.A.¥; lovastatin and simvastatin from Toronto Research Chemicals ¤North York, ON, Canada¥; saquinavir mesylate from The United States Pharmacopeial Convention ¤Rockville, MD, U.S.A.¥; and Ç-NADPH from Oriental Yeast Co., Ltd. ¤Tokyo, Japan¥. All other reagents and solvents were of analytical grade and were commercially available. Pooled intestinal and liver microsomes from humans ªHIM, pool of 18 ¤male 11, female 7¥ and HLM, pool of 50 ¤male 29, female 21¥, respectively« were purchased from Xenotech, LLC ¤Lenexa, KS, U.S.A.¥.
In vitro metabolic stability of CYP3A substrates in intestinal and liver microsomes: CYP3A substrates were individually incubated at 37ôC in 100 µL of reaction mixture consisting of 50 mM phosphate buffer ¤pH 7.4¥, HIM or HLM, and 3 mM NADPH. The linearity of metabolic activity for the microsomal concentration ¤0.01® 0.2 mg protein/mL¥, the substrate concentration ¤25® 200 nM¥, and the incubation time ¤15 min or 30 min¥ was confirmed and optimal reaction conditions were set for each compound. The final concentration of acetonitrile in the incubation mixture was 0.5% ¤v/v¥. After preincubation at 37ôC for 5 min, reactions were initiated by the addition of NADPH solution and stopped by the addition of 200 µL of ice-cold methanol. Control samples were incubated using the same method in the absence of NADPH and with NADPH after addition of ice-cold methanol.
The reaction mixtures were spiked with 200 µL of methanol containing the internal standard, 200 nM flecainide, and centrifuged at 4500 rpm for 10 min to remove precipitated protein. The supernatants were then filtered through 0.45-µm 96-well filter plates ¤Varian, Inc., Palo Alto, CA, U.S.A.¥ and diluted 2-fold with distilled water. A 10-µL portion was injected for high-performance liquid chromatography and tandem mass spectrometry ¤HPLC-MS/MS¥.
In vitro metabolic stability of UGT substrates in intestinal and liver microsomes: Incubation was performed as described previously.
13,14¥ UGT substrates were individually incubated at 37ôC in 100 µL of reaction mixture consisting of 50 mM phosphate buffer, HIM or HLM, 3.4 mM magnesium chloride, 1.15 mM EDTA, 115 µM saccharic acid lactone, 5 mM UDPGA, and 3 mM NADPH. The microsomes were activated by the addition of alamethicin at a final concentration of 20 µg/mg microsomal protein and left on ice for 15 min. After preincubation at 37ôC for 5 min, the reaction was then initiated by the addition of a combined cofactor solution containing 5 mM UDPGA and 3 mM NADPH. Substrate concentrations in the final incubation were 200 nM. The final concentration of acetonitrile in the incubation mixture was 0.5% ¤v/v¥. Microsomal protein concentrations in the incubations were 0.2®1 mg/mL. Control samples were incubated using the same method in the absence of combined cofactor solution and with combined cofactor solution after the addition of ice-cold methanol. The duration of the incubations was 5, 15, or 60 min.
The reaction mixtures were spiked with 200 µL of methanol containing the internal standard, 200 nM flecainide, and centrifuged at 4500 rpm for 10 min to remove precipitated protein. The supernatants were then filtered through 0.45-µm 96-well filter plates ¤Varian, Inc., Palo Alto, CA, U.S.A.¥ and diluted 2-fold with distilled water. A 10-µL portion was injected for HPLC-MS/MS.
The fraction unbound in microsomal incubations: The unbound fractions in microsomal incubations ¤ fu mic ¥ for all compounds were determined using highthroughput dialysis. Dialysis membranes had a 10-kDa molecular mass cutoff and were purchased from Harvard Apparatus ¤Holliston, MA, U.S.A.¥. Compounds ¤1 µM, final¥ with 0.2 or 1 mg protein/mL HIM or HLM in 50 mM phosphate buffer ¤pH 7.4¥ were added to the acceptor chambers and 50 mM phosphate buffer ¤pH 7.4¥ was added to the donor chamber. The dialysis plate was placed in an incubator at 37ôC for 22 h on a plate rotator. After equilibrium was reached, 30 µL of samples from the acceptor chamber were mixed with 30 µL of 50 mM phosphate buffer ¤pH 7.4¥ and 30 µL of samples from the donor chamber were mixed with 30 µL of 0.2 or 1 mg protein/mL microsomes in 50 mM phosphate buffer ¤pH 7.4¥. These samples were then mixed with 240 µL of methanol containing the internal standard, 200 nM flecainide, and centrifuged at 4500 rpm for 10 min to remove precipitated protein. The supernatants were then filtered using 0.45-µm 96-well filter plates ¤Varian, Inc., Palo Alto, CA, U.S.A.¥ and diluted 2-fold with distilled water for HPLC-MS/MS.
Parallel artificial membrane permeability assay: PAMPA was carried out using a PAMPA Evolution instrument from pION INC. ¤Woburn, MA, U.S.A.¥.
15¥
The lipid solution consisted of a 20% ¤w/v¥ dodecane solution and lecithin mixture. The donor solutions consisted of test compounds dissolved in 10 mM dimethylsulfoxide diluted in pH 7.4 buffer ¤final concentration of 50 µM¥. The acceptor solution was adjusted to pH 7.4. The test plate was incubated for 240 min at room temperature in a humiditysaturated atmosphere. The concentration of each test compound in the reference, donor, and acceptor plates was measured with a UV plate reader. The apparent permeability coefficient ¤P app ¥ was calculated using PAMPA Evolution software ¤pION Inc.¥.
Analytical procedure:
Concentrations of CYP3A substrates and UGT substrates in samples were measured using an HPLC-MS/MS system consisting of a TSQ 7000 mass spectrometer ¤Thermo Fisher Scientific Inc., Waltham, MA, USA¥ with a Shimadzu 10A series HPLC system ¤Shimadzu Corporation, Kyoto, Japan¥; a TSQ Quantum Ultra mass spectrometer ¤Thermo Fisher Scientific Inc.¥ with a Shimadzu 20A series HPLC system ¤Shimadzu Corporation¥; an API4000 mass spectrometer ¤Applied Biosystems, Forester City, CA, U.S.A.¥ with a Shimadzu 10A series HPLC system; or an API3200QTrap mass spectrometer ¤Applied Biosystems¥ with a Shimadzu 20A series HPLC system. Chromatography was performed using Inertsil ODS-3 columns ¤3-µm particle size, 2.1 ' 50 mm, GL Science, Tokyo, Japan¥ warmed to 40ôC. The mobile phase consisted of 0.1% formic acid ¤A¥ and methanol ¤B¥. The flow rate was 0.2 ml/min, and the gradient conditions for elution were as follows: gradient ªmin, B%« © ª0, 10«-ª1, 90«-ª4, 90«-ª4.1, 10«-ª7, 10« when measuring lovastatin and simvastatin or gradient ªmin, B%« © ª0, 10«-ª1, 90«-ª3, 90«-ª3.1, 10«-ª6, 10« when measuring the others. Mass spectrometry detection was performed by positive ionization electrospray. The selective reaction monitoring mode was used as follows to monitor ions ¤m/z: precursor ion G product ion¥: atorvastatin ¤559.3 G 439.9¥, buspirone ¤386.0 G 122.0¥, carbamazepine ¤237.0 G 194.0¥, cisapride 
The fu mic values for 0.2 or 1 mg protein/mL were calculated using Eq. 2, and the mean of duplicate determinations were calculated. Furthermore, the fu mic value for each microsomal concentration necessary was estimated using the Langmuir equation assuming that the protein binding concentration is proportional to the free concentration ¤Eq. 3¥.
fu mic, 0:2 or 1 mg protein=mL ¼ peak area in buffer sample=peak area internal standard peak area in microsomal sample=peak area internal standard ð2Þ
where B max represents the concentration of binding sites and K d represents the dissociation constant.
F g is the fraction of the dose that escapes intestinal firstpass metabolism in the enterocytes and penetrates into the blood flow of the portal vein. 6¥ Because it was considered that the intracellular free fraction of compounds is involved in not only metabolic activity but also membrane permeability, the unbound fraction in the enterocytes was not taken into consideration ¤Eq. 4¥.
where CL perm represents permeability across the basal membrane, CL met represents metabolic clearance, and f u,intestine represents the unbound fraction in the enterocytes. For CYP3A and UGT substrates, CL met was obtained from CL int,HIM or CL int,HLM . For CYP3A substrates, CL met was calculated from CL int,HLM in Eq. 5 using the ratio between CL int,HIM and CL int,HLM ¤Fig. 1¥:
CL perm was obtained by PAMPA at pH 7.4 because the clearance means the permeability across the basal membrane with a pH of 7.4 on both sides. 
Calculation of F g¤observed¥ in humans by i.v./oral method:
F g,human¤observed¥ values were calculated using Eqs. 9®11, as follows ¤Table 1¥:
where CL h,p is hepatic clearance on a plasma basis, CL tot,p is total body clearance on a plasma basis, CL r,p is renal clearance on a plasma basis ¤assumed to be 0 for troglitazone¥, Q h ¤23 ml/min/kg¥ is the hepatic blood flow in humans, R b is the blood-to-plasma concentration ratio, F a is the fraction absorbed, F is bioavailability, and F h is hepatic availability.
Calculation of F g¤observed¥ in humans by the grapefruit juice method: Grapefruit juice ¤GFJ¥ interaction studies represent a useful tool to estimate intestinal availability for CYP3A4 substrates in humans, because GFJ inhibits only intestinal CYP3A in many cases. 16¥ Therefore, F g,human¤observed¥ was calculated using Eq. 12 for buspirone, 16¥ indinavir, 17¥ and terfenadine 18¥ which could not be calculated using Eqs. 9®11: Because not reported, F a assumed to be 1. c The data was not available. The data could not be calculated.
It was assumed that concomitant administration of GFJ has no effect on the fraction of the investigated drugs absorbed or on hepatic CYP3A activity.
Results
Correlations of CL int values between intestinal and liver microsomes in humans for CYP3A substrates and UGT substrates:
The relationship between CL int values for intestinal and liver microsomes in humans is shown in Relationship between CL int,HIM and F g,human¤observed¥ for CYP3A substrates and UGT substrates: CL int,HIM and F g,human¤observed¥ values are shown in Table 2 and Figure 2A . Most of the compounds that showed high F g,human¤observed¥ values among the CYP3A substrates and UGT substrates exhibited low intestinal CL int values. However, the relationship between CL int,HIM and F g,human¤observed¥ was not consistent. In particular, atorvastatin and buspirone were Figure 2B . As with the relationship between CL int,HIM and F g,human¤observed¥ , the relationship between CL int,HLM and F g,human¤observed¥ were not consistent. In particular, atorvastatin and buspirone were extremely anomalous.
Relationship between P app,PAMPA and P app,Caco-2 : P app,PAMPA data investigated in the present study for 24 compounds and P app,Caco-2 data derived from the literature for 13 compounds are shown in Table 2 . P app,PAMPA values ranged from 3.7 to 100 ¤10 %6 cm/s¥ for atorvastatin and diazepam, respectively, and P app,Caco-2 values ranged from 0.4 to 32.4 ¤10 %6 cm/s¥ for saquinavir and midazolam, respectively. P app,Caco-2 values for indinavir and saquinavir were considerably lower than the corresponding P app,PAMPA values ªP app,Caco-2 vs P app,PAMPA ; 1.2 vs 30.2 ¤10 %6 cm/s¥ for indinavir, 0.4 vs 22.6 ¤10 %6 cm/s¥ for saquinavir«. Prediction of F g,human : The model in the present study using PAMPA could predict F g,human well for compounds other than buspirone ¤Table 2 and Fig. 3A¥ . By using CL met corrected by the ratio between CL int,HIM and CL int,HLM for CYP3A substrates, HLM showed equivalent predictability to that of HIM for CYP3A substrates ¤Figs. 3A and 3B¥.
Discussion
To select high bioavailability compounds among candidate drugs, it is necessary to predict first-pass metabolism in the intestine. The purpose of the present study was to develop a simplified in vitro®in vivo prediction method of intestinal first-pass metabolism for CYP3A substrates in humans. Furthermore, prediction of F g,human of UGT substrates was attempted using this method. F g,human was calculated for 19 CYP3A substrates and 5 UGT substrates using in vitro metabolic clearance values and permeability values obtained from in vitro metabolic stability assays in human microsomes and PAMPA at pH 7.4, respectively. F g,human¤observed¥ was calculated using the i.v./oral method for most compounds, but R b or F a was assumed to be 1 for some of the compounds ¤Table 1¥. On the other hand, the GFJ method does not require consideration of R b and F a in most cases. Because the i.v./oral method and the GFJ method had similar predictability for these CYP3A substrates other than saquinavir ¤F g,human¤observed¥ for saquinavir by GFJ method was 0.54¥, this assumption did not have a significant effect on predictability in the present study.
6¥
However, the GFJ method has disadvantages because it is based on some assumptions, as indicated in Materials and Methods. For saquinavir, F g,human calculated from i.v./oral data when the drug was given with GFJ was B1.
16¥
Therefore, it is highly possible that the F g,human¤observed¥ for saquinavir by the GFJ method was not assessed correctly.
Buspirone was identified as an outlier ¤Fig. 3¥. The F g,observed value of buspirone was calculated from a GFJ interaction study because it could not be calculated from i.v. and oral data ¤CL h h Q h ¥. However, in the GFJ interaction study, the alteration of elimination half-life reported after extensive exposure to GFJ in the study led to underestimation of F g,human¤observed¥ .
16¥ Therefore, the F g,observed value of buspirone used in the present study might be lower than the actual value; Gertz et al. used 0.21 as the F g,observed value. Kato et al. reported that F a F g was markedly reduced when the hepatic clearance was more than 100 mL/min/kg, and this in vivo intrinsic clearance corresponds to an in vitro intrinsic clearance of 0.078 mL/min/mg human liver microsomal protein. 25¥ The results in the present study were in line with the report by Kato et al. ¤Fig. 2B¥. Kadono et al. proposed a method of predicting F g in humans for highly permeable compounds. 26¥ They constructed a simplified F g model using only metabolic parameters. On the other hand, in the present study, although most of the compounds that had a high F g,human¤observed¥ exhibited low CL int values, as they did in the report by Kadono et al., the relationship between CL int and F g,human was not consistent, especially for atorvastatin and buspirone ¤Table 2 and Fig. 2¥ . The dataset in the reports by Kato et al. and Kadono et al. did not include these compounds. These results show that F g,human is influenced not only by intrinsic metabolic activities but also by other factors, and we should take these factors into account when predicting F g,human . Atorvastatin had the lowest permeability among investigated compounds in the present study ªP app,PAMPA¤pH 7.4¥ © 3.7 ¤10 %6 cm/s¥«, and it had a relatively low F g,human¤observed¥ ¤0.39¥ despite appearing to have a low CL int,HIM value ¤0.03 mL/min/mg protein¥ ¤Table 2¥. For these reasons, permeability was taken into consideration. F g,human¤predicted¥ for atorvastatin ¤0.55¥ became closer to F g,human¤observed¥ after taking permeability into consideration ¤Fig. 3A¥. Similarly, diclofenac had a low permeability ªP app,PAMPA¤pH 7.4¥ © 8.1 ¤10 %6 cm/s¥«, and predictability of F g,human for diclofenac was improved by incorporating P app,PAMPA . In fact, when we calculated using the method of Kadono et al. with our data, the prediction accuracy was similar to that using our method for highpermeability compounds, whereas the prediction accuracy was lower than that using our method for atorvastatin and diclofenac. Therefore, the predictability of F g,human was improved for lower permeability compounds by taking permeability into consideration using PAMPA at pH 7.4, which is widely used in the pharmaceutical industry at the earliest primary screening stage.
In the present study, permeability values were obtained by PAMPA at pH 7.4, because the values represent the permeability across the basal membrane with a pH of 7.4 on both sides. P app,Caco-2 values for indinavir and saquinavir were considerably lower than the corresponding P app,PAMPA values ¤Table 2¥. The main cause might be potent excretion of these compounds by P-gp in Caco-2 cells. 32¥ Had the P app,Caco-2 values been used to calculate the permeability, the model might have yielded largely underestimated F g,human¤predicted¥ values because the P app,Caco-2 values included excretion by P-gp across the apical membrane. Therefore, our proposal of using PAMPA at pH 7.4 was more appropriate for prediction of F g,human than the method using cell lines. The Q gut model using P app,Caco-2 largely underestimated F g,human for saquinavir and indinavir, and overestimated F g,human for atorvastatin and buspirone. On the other hand, the model in the present study could predict F g,human for these compounds comparatively well. For example, F g,human¤observed¥ , F g,human ¤predicted¥ by this model, and F g,human ¤predicted¥ by the Q gut model are 0.19, 0.11, and 0.01 for saquinavir; 1.0, 0.81, and 0.25 for indinavir; 0.39, 055, and 0.90 for atorvastatin; and 0.11, 0.64, and 0.68 for buspirone, respectively.
5¥
CYP3A content has been found to rise slightly from the duodenum to the middle jejunum and then decline to the distal jejunum and ileum. 33¥ Because absorption sites differ from compound to compound, there is a possibility that the prediction accuracy could be further improved by taking into consideration the differences in CYP3A content. In the present study, this factor was not taken into consideration because the purpose was to construct a practical and simplified method. In this study, compounds were incubated in 50 mM phosphate buffer when estimating CL int,HIM or CL int,HLM . Because the choice of ion-strength for in vitro incubations may affect the rates of metabolism, the A value should be calculated under each condition when using different salt conditions. For CYP3A substrates, the CL int values in the intestine appeared to be lower, but they correlated well with those in the liver ¤Fig. 1¥. These results are consistent with reports that the K m values of CYP3A substrates exhibit good correspondence between human intestinal and liver microsomes, 34,35¥ identical CYP3A4 proteins are expressed in both tissues, 36¥ and the average CYP3A4 content was 76.0 and 23.6 pmol/mg protein in the liver and intestine, respectively. 37¥ For UGT substrates, intestinal CL int values showed a poor correlation with hepatic CL int values. These results are consistent with the fact that tissue-dependent distributions of various UGT isoforms have been identified.
11¥
By using CL met corrected by the ratio of CL int,HIM to CL int,HLM for CYP3A substrates, HLM showed equivalent predictability to that of HIM for CYP3A substrates ¤Figs. 3A and 3B¥. This will be useful to predict F g,human using CL int,HLM at the drug discovery stage, because only CL int,HLM is investigated by high-throughput screening in many cases. On the other hand, it is difficult to predict F g,human using the CL int,HLM values for UGT substrates because there is no reported information about expression levels of UGT isoforms in human intestine and liver.
UGT substrates showed a similar relationship between CL int,HIM and F g,human to that for CYP3A substrates ¤Table 2 and Fig. 2A¥ . Furthermore, F g,human¤predicted¥ of UGT substrates showed good correspondence with F g,human¤observed¥ ¤Table 2 and Fig. 3A¥ . These results showed that the present method is applicable to prediction of F g,human for UGT substrates. In human intestine, UGT contributed to the metabolism of diclofenac, gemfibrozil, raloxifene, and telmisartan almost completely, and troglitazone was metabolized by not only UGT but also CYP ¤the fraction of troglitazone metabolized by UGT was 0.74 in HIM¥.
28,38¥
Human intestine expresses a range of UGTs, including UGT1A1 and UGT2B7 ¤as in the liver¥, in addition to the intestine-specific enzymes UGT1A8, and UGT1A10.
39¥
Diclofenac and gemfibrozil are metabolized by UGT2B7. Raloxifene is metabolized by UGT1A1, UGT1A8, and UGT1A10. Troglitazone is metabolized by UGT1A1 and UGT1A10. 40¥ These facts indicate the applicability of combined cofactor conditions in the assessment of intestinal metabolism for compounds with a differential contribution of P450 and various UGT isoforms. Kilford et al. reported that improved predictability of liver microsomal data is observed in the presence of bovine serum albumin ¤BSA¥, in particular for UGT2B7 substrates. Addition of 2% BSA resulted in 6-to 13-fold increases in hepatic CL int for diclofenac and gemfibrozil, respectively. 14¥ However, the method using CL int values in intestinal microsomes without BSA in the present study showed good prediction for 5 UGT substrates, including UGT2B7 substrates diclofenac and gemfibrozil. Therefore, there is a possibility that BSA is not necessary for prediction of F g,human of UGT substrates.
The present method using CL int in human microsomes and P app,PAMPA , which can be established easily, may be useful in predicting F g,human at the drug discovery stage. Because there was no compound in which F g,human was badly underestimated in this study, this method might avoid erroneously eliminating compounds among candidates that exhibit good F g,human . In the next stage of drug candidate selection, an in vivo model reported previously using cynomolgus monkeys is suitable for more accurate prediction for CYP3A substrates.
6¥
A simplified method was developed for predicting F g,human that is applicable to low-permeability compounds based on a new concept, using metabolic clearance from metabolic stability assays in HIM ¤for both CYP3A and UGT substrates¥ or HLM ¤for only CYP3A substrates¥ and permeability values from PAMPA at pH 7.4. We conclude from our findings that this method will be useful at the early stage in selection of candidate drugs because it was able to predict F g,human for most of the compounds investigated.
